Olaris, founded in 2014 by Liz O’Day, is using “biomarkers of response” to determine the best possible course of drugs to treat patients most effectively.
Olaris, founded in 2014 by Liz O’Day, is using “biomarkers of response” to determine the best possible course of drugs to treat patients most effectively.